Feds Detail Plan to Prevent Abuse of Buprenorphine February 25, 2008
News Summary
Federal drug officials recently detailed a plan to control diversion and abuse of an anti-addiction medication that was specifically designed to resist such problems, the Baltimore Sun reported Feb. 23.
An expert panel recently concluded a two-day, closed-door meeting to discuss buprenorphine, a medication designed to treat opiate abuse and billed as a doctor-prescribed alternative to clinic-oriented methadone maintenance. The drug, primarily sold under the brand name Suboxone, was designed by the National Institute on Drug Abuse and pharmaceutical firm Reckitt Benckiser to be resistant to addicts crushing the pills and injecting them.
But experts say that addicts are nonetheless doing exactly that to get high, as well as selling it on the street. "The issue of diversion has been out there since 2004," said Dr. H. Westley Clark, director of the Center for Substance Abuse Treatment. "We've been concerned about that, and we will continue to be concerned about that."
The expert panel called for sterner warning labels on the drug, better training for physicians who prescribe it, and for improved monitoring of prescriptions and drug supplies. Former NIDA head Charles Schuster said, for example, that doctors need to be more cautious about prescribing 30-day supplies of the drug.
"A small minority of doctors are not practicing good medicine," Schuster said. "That's a problem we need to be concerned with."
Buprenorphine has been praised as highly effective at curbing withdrawal symptoms, and the drug's wider availability has allowed many opiate addicts with limited or no access to methadone programs to get treatment. About 170,000 people have prescriptions to buprenorphine.
This article has been revised to reflect the following correction:
Correction: February 26, 2008
The original version of this news summary described a "two-day, closed-door meeting to discuss problems associated with buprenorphine." The source story reported only that the meeting was held to discuss buprenorphine, and did not explicitly state that problems with the medication were the focus of the summit.
COMMENTS ON THIS ARTICLE: